RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+28.15%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$1.31B
AUM Growth
+$1.31B
(+9.2%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-10.7%
Top 10 Holdings %
Top 10 Hldgs %
78.43%
Holding
36
New
9
Increased
2
Reduced
10
Closed
5
Top Buys
| 1 |
TG Therapeutics
TGTX
|
$35.1M |
| 2 |
Solid Biosciences
SLDB
|
$20.2M |
| 3 |
Clearside Biomedical
CLSD
|
$16.4M |
| 4 |
Gyre Therapeutics
GYRE
|
$13.3M |
| 5 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$13.3M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$87.6M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$42.1M |
| 3 |
InflaRx
IFRX
|
$36.2M |
| 4 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$22.7M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$17.7M |
Sector Composition
| 1 | Healthcare | 97.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Wave Life Sciences
WVE
$1.53B
| $301M | 23.08% | 7,512,049 | – | – |
|
|
2
Ascendis Pharma
ASND
$11.8B
| $277M | 21.25% | 4,240,536 -1,340,154 | -24% | -$87.6M |
|
|
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
| $127M | 9.74% | 1,028,289 -142,989 | -12% | -$17.7M |
|
|
MYOV
4
DELISTED
Myovant Sciences Ltd.
MYOV
| $60.2M | 4.61% | 2,830,455 | – | – |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $56.9M | 4.36% | 353,133 -102,040 | -22% | -$16.4M |
|
|
6
InflaRx
IFRX
$108M
| $46.7M | 3.58% | 1,620,653 -1,255,427 | -44% | -$36.2M |
|
|
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
| $45.9M | 3.51% | 1,145,268 | – | – |
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $37.6M | 2.88% | 3,933,489 -1,032,024 | -21% | -$9.87M |
|
9
scPharmaceuticals
SCPH
$295M
| $35.4M | 2.71% | 2,857,143 | – | – |
|
|
ECYT
10
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $35.3M | 2.7% | 3,881,793 +517,145 | +15% | +$4.7M |
|
|
11
TG Therapeutics
TGTX
$4.65B
| $35.1M | 2.69% | +2,472,344 | New | +$35.1M |
|
12
KALA BIO
KALA
$78.8M
| $33.5M | 2.56% | 2,113,236 | – | – |
|
13
BioCryst Pharmaceuticals
BCRX
$1.74B
| $33.3M | 2.55% | 6,984,692 | – | – |
|
|
RARX
14
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $20.5M | 1.57% | 3,851,808 +2,500,000 | +185% | +$13.3M |
|
|
15
Solid Biosciences
SLDB
$427M
| $20.2M | 1.55% | +2,689,444 | New | +$20.2M |
|
16
Apellis Pharmaceuticals
APLS
$3.48B
| $19.9M | 1.52% | 900,000 | – | – |
|
|
17
Clearside Biomedical
CLSD
$28.9M
| $16.4M | 1.25% | +1,525,000 | New | +$16.4M |
|
|
AVEO
18
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $14.7M | 1.12% | 5,062,759 | – | – |
|
19
KalVista Pharmaceuticals
KALV
$678M
| $13.7M | 1.05% | 1,441,070 | – | – |
|
|
20
Gyre Therapeutics
GYRE
$703M
| $13.3M | 1.02% | +514,917 | New | +$13.3M |
|
21
Iovance Biotherapeutics
IOVA
$807M
| $11.1M | 0.85% | +659,059 | New | +$11.1M |
|
22
Spero Therapeutics
SPRO
$116M
| $10.6M | 0.81% | 741,647 -484,000 | -39% | -$6.9M |
|
|
BHVN
23
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $9.37M | 0.72% | 363,636 -1,633,642 | -82% | -$42.1M |
|
24
Viking Therapeutics
VKTX
$3.04B
| $8.87M | 0.68% | +2,029,396 | New | +$8.87M |
|
|
VIRX
25
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $6.72M | 0.52% | 2,471,456 -625,384 | -20% | -$1.7M |
|